Many players in BCL-2 family affairs.

During apoptotic cell death, cellular stress signals converge at the mitochondria to induce mitochondrial outer-membrane permeabilization (MOMP) through B cell lymphoma-2 (BCL-2) family proteins and their effectors. BCL-2 proteins function through protein-protein interactions, the mechanisms and structural aspects of which are only now being uncovered. Recently, the elucidation of the dynamic features underlying their function has highlighted their structural plasticity and the consequent complex thermodynamic landscape governing their protein-protein interactions. These studies show that canonical interactions involve a conserved, hydrophobic groove, whereas non-canonical interactions function allosterically outside the groove. We review the latest structural advances in understanding the interactions and functions of mammalian BCL-2 family members, and discuss new opportunities to modulate these proteins in health and disease.

[1]  L. Walensky,et al.  Direct activation of full-length proapoptotic BAK , 2013, Proceedings of the National Academy of Sciences.

[2]  E. Morselli,et al.  Targeting post-mitochondrial effectors of apoptosis for neuroprotection. , 2009, Biochimica et biophysica acta.

[3]  Brian A. Chauder,et al.  Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. , 2013, Journal of medicinal chemistry.

[4]  G. Cohen,et al.  ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets , 2013, British journal of haematology.

[5]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[6]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[7]  B. Corfe,et al.  Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis , 1999, The Journal of cell biology.

[8]  J. Risk,et al.  Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets , 2007, Cell Death and Differentiation.

[9]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[10]  K. J. Oh,et al.  Organization of the Mitochondrial Apoptotic BAK Pore , 2013, The Journal of Biological Chemistry.

[11]  D. Green,et al.  Transcription, apoptosis and p53: catch-22. , 2005, Trends in genetics : TIG.

[12]  W. Handke,et al.  Cytomegaloviruses inhibit Bak- and Bax-mediated apoptosis with two separate viral proteins , 2010, Cell Death and Differentiation.

[13]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[14]  R. Hotchkiss,et al.  Cell death. , 2009, The New England journal of medicine.

[15]  D. Chang,et al.  Dynamics and structure of the Bax-Bak complex responsible for releasing mitochondrial proteins during apoptosis , 2008, Journal of Cell Science.

[16]  P. Colman,et al.  To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. , 2008, Molecular cell.

[17]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[18]  D. Green,et al.  A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.

[19]  J. Leverson,et al.  Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo , 2012, British journal of pharmacology.

[20]  Osamu Takeuchi,et al.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. , 2009, Molecular cell.

[21]  Y. Muto,et al.  Dual-site Interactions of p53 Protein Transactivation Domain with Anti-apoptotic Bcl-2 Family Proteins Reveal a Highly Convergent Mechanism of Divergent p53 Pathways* , 2013, The Journal of Biological Chemistry.

[22]  D. Green,et al.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.

[23]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[24]  M. Hinds,et al.  Structural biology of the Bcl-2 family and its mimicry by viral proteins , 2013, Cell Death and Disease.

[25]  C. Day,et al.  Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. , 2009, Molecular cell.

[26]  D. Green,et al.  Apoptotic Pathways: Ten Minutes to Dead , 2005, Cell.

[27]  A. Petros,et al.  Structural biology of the Bcl-2 family of proteins. , 2004, Biochimica et biophysica acta.

[28]  H. Steinhoff,et al.  Molecular Details of Bax Activation, Oligomerization, and Membrane Insertion* , 2009, The Journal of Biological Chemistry.

[29]  A. Tocilj,et al.  The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. , 2006, Molecular cell.

[30]  D. Andrews,et al.  Shedding Light on Apoptosis at Subcellular Membranes , 2012, Cell.

[31]  D. Green,et al.  The BCL-2 family reunion. , 2010, Molecular cell.

[32]  A. Letai,et al.  Mitochondria: gatekeepers of response to chemotherapy. , 2013, Trends in cell biology.

[33]  Matthew E. Ritchie,et al.  Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. , 2013, Cancer cell.

[34]  C. Tse,et al.  The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo , 2011, Molecular Cancer Therapeutics.

[35]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[36]  K. Gehring,et al.  Heterodimerization of BAK and MCL-1 Activated by Detergent Micelles* , 2010, The Journal of Biological Chemistry.

[37]  G. Dewson,et al.  Assembly of the Bak Apoptotic Pore , 2013, The Journal of Biological Chemistry.

[38]  J. Hickman,et al.  Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members , 2009, The Journal of cell biology.

[39]  L. Walensky,et al.  Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. , 2013, Chemistry & biology.

[40]  D. Andrews,et al.  Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis , 2005, The EMBO journal.

[41]  A. Fersht,et al.  Comparative Biophysical Characterization of p53 with the Pro-apoptotic BAK and the Anti-apoptotic BCL-xL* , 2007, Journal of Biological Chemistry.

[42]  G. Dewson,et al.  Bax dimerizes via a symmetric BH3:groove interface during apoptosis , 2011, Cell Death and Differentiation.

[43]  Evripidis Gavathiotis,et al.  A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. , 2012, The Journal of clinical investigation.

[44]  C. Tse,et al.  ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[45]  D. Green,et al.  Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.

[46]  S. Chi,et al.  Molecular Basis of Bcl-XL-p53 Interaction: Insights from Molecular Dynamics Simulations , 2011, PloS one.

[47]  Y. Pang,et al.  Evaluation of the BH3-only Protein Puma as a Direct Bak Activator* , 2013, The Journal of Biological Chemistry.

[48]  A. Gunasekera,et al.  Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.

[49]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[50]  W. Handke,et al.  Live or let die: manipulation of cellular suicide programs by murine cytomegalovirus , 2012, Medical Microbiology and Immunology.

[51]  J. Hsieh,et al.  Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.

[52]  L. Walensky,et al.  BH3-triggered structural reorganization drives the activation of proapoptotic BAX. , 2010, Molecular cell.

[53]  V. Gandhi,et al.  Bcl-2 antagonists: a proof of concept for CLL therapy , 2013, Investigational New Drugs.

[54]  L. Walensky.  Direct BAKtivation , 2013, Nature Structural &Molecular Biology.

[55]  Brian J. Smith,et al.  Structure-guided design of a selective BCL-X(L) inhibitor. , 2013, Nature chemical biology.

[56]  Renaldo Mendoza,et al.  Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. , 2010, Bioorganic & medicinal chemistry letters.

[57]  T. Kuwana,et al.  PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53 , 2005, Science.

[58]  J. Opferman,et al.  Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. , 2013, Genes & development.

[59]  Nico Tjandra,et al.  Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol , 2011, Cell.

[60]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[61]  Y. Hsu,et al.  Nonionic Detergents Induce Dimerization among Members of the Bcl-2 Family* , 1997, The Journal of Biological Chemistry.

[62]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[63]  Richard W. Kriwacki,et al.  PUMA Binding Induces Partial Unfolding within BCL-xL to Disrupt p53 Binding and Promote Apoptosis , 2012, Nature chemical biology.

[64]  T. Kuwana,et al.  BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak* , 2010, The Journal of Biological Chemistry.

[65]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[66]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[67]  H. Horvitz,et al.  Xk-Related Protein 8 and CED-8 Promote Phosphatidylserine Exposure in Apoptotic Cells , 2013, Science.

[68]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[69]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[70]  M. Hahne,et al.  Cell Death , 2010, Cell Death and Differentiation.

[71]  Y. Pang,et al.  Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization , 2011, The Journal of cell biology.

[72]  M. Butterworth,et al.  Evaluation and critical assessment of putative MCL-1 inhibitors , 2013, Cell Death and Differentiation.

[73]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[74]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[75]  Philippe Juin,et al.  The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. , 2004, Molecular cell.

[76]  Roland L. Dunbrack,et al.  Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain* , 2008, Journal of Biological Chemistry.

[77]  Harry Jubb,et al.  Protein-protein interactions as druggable targets: recent technological advances. , 2013, Current opinion in pharmacology.

[78]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[79]  D. Green,et al.  BID-induced structural changes in BAK promote apoptosis , 2013, Nature Structural &Molecular Biology.

[80]  C. Klein,et al.  BclxL Changes Conformation upon Binding to Wild-type but Not Mutant p53 DNA Binding Domain* , 2009, The Journal of Biological Chemistry.

[81]  Xu Luo,et al.  A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. , 2007, Genes & development.

[82]  K. Gehring,et al.  Apoptotic Regulation by MCL-1 through Heterodimerization* , 2010, The Journal of Biological Chemistry.

[83]  Junying Yuan,et al.  Solution Structure of BID, an Intracellular Amplifier of Apoptotic Signaling , 1999, Cell.

[84]  Erinna F. Lee,et al.  Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. , 2008, Journal of molecular biology.

[85]  A. Petros,et al.  Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies , 2000, Protein science : a publication of the Protein Society.

[86]  Xiaodong Wang,et al.  Cytochrome C-mediated apoptosis. , 2003, Annual review of biochemistry.

[87]  S. Jonjić,et al.  Viral Inhibition of BAK Promotes Murine Cytomegalovirus Dissemination to Salivary Glands , 2013, Journal of Virology.

[88]  S. Chi,et al.  The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif. , 2009, Biochemistry.

[89]  Patrick Dumont,et al.  Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex , 2004, Nature Cell Biology.

[90]  L. Walensky,et al.  Direct and selective small-molecule activation of proapoptotic BAX. , 2012, Nature chemical biology.

[91]  M. Amiot,et al.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma , 2013, Leukemia.

[92]  Erinna F. Lee,et al.  Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis , 2013, Cell.

[93]  D. Andrews,et al.  BH3-only proteins: Orchestrators of apoptosis. , 2011, Biochimica et biophysica acta.

[94]  N. Tjandra,et al.  Structural mechanism of Bax inhibition by cytomegalovirus protein vMIA , 2012, Proceedings of the National Academy of Sciences.

[95]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[96]  C. Tse,et al.  Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models , 2008, Clinical Cancer Research.

[97]  D. Green,et al.  Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. , 2003, Cancer cell.

[98]  D. Andrews,et al.  Mechanisms of action of Bcl-2 family proteins. , 2013, Cold Spring Harbor perspectives in biology.

[99]  R. Youle,et al.  Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[100]  A. Strasser,et al.  BH3-only proteins in apoptosis at a glance , 2012, Journal of Cell Science.

[101]  Ryung S. Kim,et al.  Conformational Changes in BAK, a Pore-forming Proapoptotic Bcl-2 Family Member, upon Membrane Insertion and Direct Evidence for the Existence of BH3-BH3 Contact Interface in BAK Homo-oligomers* , 2010, The Journal of Biological Chemistry.

[102]  V. Mootha,et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. , 2000, Genes & development.

[103]  Chengyu Liang,et al.  Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX , 2011, Cell Research.

[104]  Horst Kessler,et al.  WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.

[105]  Osamu Takeuchi,et al.  BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program , 2010, Science.